Acambis on hold by Jefferies

Jefferies & Co., Inc. analyst Robin Campbell rated Acambis plc at hold. Unpredictable revenues in 2006 have attributed to the analyst's revision to forecasts for the Japanese encephalitis vaccine. Second-quarter results led to downgraded forecasts as well. The analyst is also looking at the requisition framework for Project BioShield. Shares of the Cambridge, England-based pharmaceutical company were up 6.00p, or 4.17%, at 150.00p. (London: ACM)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.